MTOR and familial pancreatic carcinoma: Furthermore, SOM230 was shown to be at least as potent as the mTORC1 (RAD001) and mTOR (PP242) inhibitors at suppressing protein synthesis and re-sensitizing pancreatic cancer cells to gemcitabine cytotoxicity (Supplementary Fig S4B–C).